ASX-LISTED Medlab is expecting a total of around 500 attendees at a series of medical education seminars in Sydney, Melbourne and Brisbane this month, which it says are in keeping with the requirements of the TGA's Special Access Scheme for its Nanabis nanotechnology buccal absorption cannabis product.
Topics have included human trials of Nanabis at Sydney's Royal North Shore, as well as the product's role in pain management.
The first batch of Nanabis has been manufactured in Melbourne and validated analytical release for supply is expected this week.
Medlab md Dr Sean Hall said "Nanabis is an Australian-produced medicine made to Australian standards in an Australian facility".
Once the validated release of the manufactured Nanabis product is achieved, Medlab will be in a "position to supply a drug that conforms to Australian standards for Schedule 8 medicine," he said.
Hall said Nanabis' "Nanocelle" unique delivery system would be supported by trial data, "thus giving prescribers confidence in quality and efficacy".
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Mar 18
